Systemic therapy for hepatocellular carcinoma: Chinese consensus-based interdisciplinary expert statements,Liver Cancer

当前位置： X-MOL 学术 › Liver Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Systemic therapy for hepatocellular carcinoma: Chinese consensus-based interdisciplinary expert statements
Liver Cancer ( IF 11.6 ) Pub Date : 2022-01-04 , DOI: 10.1159/000521596
Yongkun Sun ₁ , Wen Zhang ₁ , Xinyu Bi ₂ , Zhengqiang Yang ₃ , Yu Tang ₄ , Liming Jiang ₅ , Feng Bi ₆ , Minshan Chen ₇ , Shuqun Cheng ₈ , Yihebali Chi ₁ , Yue Han ₃ , Jing Huang ₁ , Zhen Huang ₂ , Yuan Ji ₉ , Liqun Jia ₁₀ , Zhichao Jiang ₁ , Jing Jin ₁₁ , Zhengyu Jin ₁₂ , Xiao Li ₃ , Zhiyu Li ₂ , Jun Liang ₁₃ , Lianxin Liu ₁₄ , Yunpeng Liu ₁₅ , Yinying Lu ₁₆ , Shichun Lu ₁₇ , Qinghua Meng ₁₈ , Zuoxing Niu ₁₉ , Hongming Pan ₂₀ , Shukui Qin ₂₁ , Wang Qu ₁ , Guoliang Shao ₂₂ , Feng Shen ₂₃ , Tianqiang Song ₂₄ , Yan Song ₁ , Kaishan Tao ₂₅ , Aiping Tian ₂₆ , Jianhua Wang ₂₇ , Wenling Wang ₂₈ , Zhe Wang ₂₉ , Liqun Wu ₃₀ , Feng Xia ₃₁ , Baocai Xing ₃₂ , Jianming Xu ₃₃ , Huadan Xue ₁₂ , Dong Yan ₃ , Lin Yang ₁ , Jianming Ying ₃₄ , Jingping Yun ₃₅ , Zhaochong Zeng ₃₆ , Xuewen Zhang ₃₇ , Yanqiao Zhang ₃₈ , Yefan Zhang ₂ , Jianjun Zhao ₂ , Jianguo Zhou ₂ , Xu Zhu ₃₉ , Yinghua Zou ₄₀ , Jiahong Dong ₄₁ , Jia Fan ₄₂ , Wan Yee Lau ₄₃ , Yan Sun ₁ , Jinming Yu ₄₄ , Hong Zhao ₂ , Aiping Zhou ₁ , Jianqiang Cai ₂

Affiliation

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of GCP Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Diagnostic Imaging, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Medical Oncology, West China Hospital, Chengdu, China.
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
The Six Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Department of Pathology, Zhongshan Hospital Fudan University, Shanghai, China.
Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Radiology, Peking Union Medical College Hospital, Beijing, China.
Department of Medical Oncology, Peking University International Hospital, Beijing, China.
Department of Hepatic Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Department of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Department of Hepatobiliary Surgery, First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Chinese PLA Medical School, Beijing, China.
Department of Clinical Care Medicine of Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Department of Medical Oncology, PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, China.
Department of Interventional Radiology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Department of Traditional Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Interventional Radiology, Zhongshan Hospital Fudan University, Shanghai, China.
Department of Radiology, The Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, China.
Department of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Department of Hepatic Biliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Hepatobiliary Surgery, The Southwest Hospital of AMU, Chongqing, China.
Department of Hepatobiliary and Pancreatic Surgery Unit I, Beijing Cancer Hospital, Beijing, China.
Department of Gastrointestinal Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Radiology, Zhongshan Hospital Fudan University, Shanghai, China.
Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, China.
Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Department of Interventional Radiology, Beijing Cancer Hospital, Beijing, China.
Department of Interventional Radiology, Peking University First Hospital, Beijing, China.
Department of Hepatopancreatobiliary Surgery, Beijing Tsinghua Changgung Hospital, Beijing, China.
Department of Liver Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Department of Hepatic Biliary Pancreatic Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Taian, China.

Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small molecular weight tyrosine kinase-inhibitor (SMW TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors (ICIs) for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists，radiologists，pathologists, orthopedic surgeons, traditional Chinese medicine physicians and interventional radiologists have reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.

更新日期：2022-01-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文